June 2, 2021

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, variants

• Sera collected from individuals with SARS-CoV-2 infection prior to April 2020 (n=18) neutralized pseudoviruses with the mutated spike proteins of variants of concern, including B.1.1.7, B.1.351, and B.1.1.248, with only a minor loss in neutralizing activity. Similarly, neutralizing activity among individuals fully vaccinated with the Pfizer-BioNTech vaccine (n=5) were only reduced up to 3-fold by spike proteins possessing the E484K mutation. By contrast, neutralizing activity of the REGN10933 monoclonal antibody was abolished by B.1.351 and B.1.1.248, reducing the Regeneron monoclonal antibody cocktail neutralizing activity by 9- to 15-fold. The individuals were infected at time points prior to the emergence of variants of concern.

Tada et al. (June 1, 2021). Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. MBio.  From https://pubmed.ncbi.nlm.nih.gov/34060334/